[go: up one dir, main page]

WO2018199130A1 - Composition destinée à améliorer la capacité de travail intellectuel et composition destinée à améliorer la capacité cognitive - Google Patents

Composition destinée à améliorer la capacité de travail intellectuel et composition destinée à améliorer la capacité cognitive Download PDF

Info

Publication number
WO2018199130A1
WO2018199130A1 PCT/JP2018/016724 JP2018016724W WO2018199130A1 WO 2018199130 A1 WO2018199130 A1 WO 2018199130A1 JP 2018016724 W JP2018016724 W JP 2018016724W WO 2018199130 A1 WO2018199130 A1 WO 2018199130A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
protein
improving
work ability
intellectual work
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/016724
Other languages
English (en)
Japanese (ja)
Inventor
佳絵 斎藤
晃幸 野間
早苗 中谷
淳 神田
伊藤　裕之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Co Ltd
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Priority to CN201880010949.6A priority Critical patent/CN110312516A/zh
Publication of WO2018199130A1 publication Critical patent/WO2018199130A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins

Definitions

  • the present invention relates to a composition for improving intellectual work ability, a method of using a protein as an intellectual work ability improver, and the like.
  • the present invention also relates to a composition for improving cognitive ability, a method of using a protein as a cognitive ability improving agent, and the like.
  • fragrance composition has a high risk of decreasing its effectiveness in a space where humans enter and exit is relatively intense.
  • volatilization range is expanded using a blower or the like, or volatilized using a heater or the like.
  • the energy consumption will increase due to the need to increase the speed.
  • An object of the present invention is to provide a composition for improving the intellectual work ability, which can efficiently supply an active ingredient to a human without consuming a great deal of energy in any space. It is to provide.
  • the composition for improving intellectual work ability comprises protein as an active ingredient. That is, the protein is used as a composition for improving intellectual work ability or as a component thereof.
  • the “composition” referred to herein includes animals such as pharmaceuticals, supplements, food additives and the like, foods and drinks (excluding animals and plants themselves), and food and drink compositions (including processed foods and drinks). Included are those that can be ingested (including humans).
  • protein is contained in this composition within the range of 2 mass% or more and 10 mass% or less.
  • the composition is preferably a liquid or beverage. Examples of the drink include milk drinks, soft drinks, carbonated drinks, nutrition drinks, fruit juice drinks, and lactic acid bacteria drinks.
  • the beverage is packed in a container, and the capacity is preferably in the range of 100 mL to 1,000 mL, or in the range of 100 g to 1,000 g.
  • the protein according to the first aspect of the present invention can activate human parasympathetic nerve activity and improve human intellectual work ability (ie, It can also be said that the composition for improving intellectual work ability is a composition for enhancing parasympathetic nerve activity). In other words, proteins can effectively improve human intellectual work ability.
  • the protein is preferably milk protein.
  • This milk protein preferably contains casein, whey protein, and the like.
  • casein when casein is contained in the composition for improving intellectual work ability, the content of casein is preferably in the range of 1.5% by mass or more and 8% by mass or less.
  • content of whey protein exists in the range of 0.5 mass% or more and 2 mass% or less.
  • the intake amount per time of this composition for improving intellectual work ability is in the range of 100 g or more and 1,000 g or less.
  • this composition for intellectual work ability improvement contains 9 mass% or less carbohydrate, or contains 8 mass% or less glucose. Moreover, it is preferable that this composition for intellectual work ability improvement does not contain lipid or contains less than 1 mass% lipid. Furthermore, it is preferable that this composition for improving intellectual work ability has a calorific value in the range of 0.2 kcal / mL to 2 kcal / mL, or in the range of 0.2 kcal / g to 2 kcal / g. .
  • the method according to the second aspect of the present invention is to provide a method for using a protein as an intellectual work ability improver, that is, a protein for use as an intellectual work ability improver.
  • the method according to the third aspect of the present invention is a method for improving human intellectual work ability by orally administering the above-described composition for improving intellectual work ability.
  • the composition for improving intellectual work ability according to the present invention has an effect quickly by a single administration, it may be administered continuously.
  • the administration period is preferably 1 week or more, more preferably 2 weeks or more, further preferably 3 weeks or more, and particularly preferably 4 weeks or more.
  • the use of the protein according to the fourth aspect of the present invention is an act for producing a composition for improving the intellectual work ability.
  • composition for improving cognitive ability contains protein as an active ingredient. That is, the protein is used as a composition for improving cognitive ability or as a component thereof.
  • the “composition” referred to herein includes animals such as pharmaceuticals, supplements, food additives and the like, foods and drinks (excluding animals and plants themselves), and food and drink compositions (including processed foods and drinks). Included are those that can be ingested (including humans).
  • protein contains 2.0 mass% or more in this composition.
  • the composition is preferably a liquid or beverage.
  • the protein according to the fifth aspect of the present invention can improve human cognitive ability. That is, the protein can effectively improve human cognitive ability.
  • protein supply source and specific example in this composition for cognitive ability improvement are the same as the protein supply source and specific example in the composition for intellectual work ability improvement.
  • protein means “protein-containing beverage” (Example), and “placebo” means “placebo beverage” (Comparative Example).
  • index RMSSD
  • protein containing drink which concerns on an Example
  • placebo drink which concerns on a comparative example.
  • protein means “protein-containing beverage” (Example)
  • placebo” means “placebo beverage” (Comparative Example).
  • protein means “protein-containing beverage” (Example)
  • placebo means “placebo beverage” (Comparative Example).
  • AUC value Absolute Under the Curve: area value under a curve
  • HF HRV parasympathetic nerve activity index
  • the composition for improving intellectual work ability contains protein as an active ingredient.
  • the type of protein is preferably milk protein, but is not particularly limited. Milk is raw milk, pasteurized milk, skim milk, whole milk powder, partially skimmed milk, skim milk powder, full fat concentrated milk, skim concentrated milk, cream, butter, buttermilk, whey, whey protein concentrate (WPC), whey protein isolate (WPI), and the like.
  • milk protein examples include caseins such as ⁇ -casein, ⁇ -casein, ⁇ -casein, and ⁇ -casein, ⁇ -lactalbumin ( ⁇ -La), ⁇ -lactoglobulin ( ⁇ - Lg), whey proteins such as lactoferrin, serum albumin, euglobulin, pseudoglobulin, proteose and peptone.
  • this composition for intellectual work ability improvement may consist only of protein, and may contain the other component.
  • the protein used in the composition for improving intellectual work ability there is a protein composed of casein and whey protein.
  • the mass ratio of casein to whey protein is preferably in the range of 10: 1 to 1:10, more preferably in the range of 7: 1 to 1: 7, and even more preferably 5: 1 to 1. : 5, particularly preferably in the range of 4: 1 to 1: 4.
  • this composition for improving intellectual work ability preferably contains, for example, casein in an amount of 1.5% by mass or more, and more preferably in the range of 1.5% by mass or more and 8% by mass or less.
  • this composition for improving intellectual work ability preferably includes, for example, 0.5% by mass of whey protein, and more preferably includes 0.5% by mass to 2% by mass.
  • the composition for improving intellectual work ability exerts its function when taken by a human.
  • the “human” here may be a human of a wide age group from infants to elderly people regardless of age or sex. That is, the composition for improving intellectual work ability can be used, for example, for improving the learning ability of a child and improving the intellectual work ability of an adult or an elderly person.
  • “ingestion” here is not limited to the intake route as long as it enters the human body, and can be realized by all known intake methods such as oral intake, tube intake, enteral intake, and the like. obtain. In this case, typical examples include oral intake and enteral intake via the digestive tract, but oral intake is preferable, and oral intake by eating and drinking is more preferable.
  • the composition for improving intellectual work ability according to the embodiment of the present invention may be any protein as long as it contains a protein, and the content thereof is not particularly limited, but the composition for improving intellectual work ability is a liquid.
  • the protein is preferably contained in an amount of 2.0% by mass or more, more preferably 3.0% by mass or more, and further preferably 3.5% by mass or more. The effect is expected to increase as the protein content increases, but the upper limit is, for example, 10% by mass.
  • the composition for improving intellectual work ability according to the embodiment of the present invention preferably includes a carbohydrate having a predetermined concentration or less, and the content thereof is not particularly limited, but for example, in the range of more than 0 mass% to 9 mass% or less. It is preferable to be within.
  • carbohydrate is glucose
  • the composition for intellectual work ability improvement which concerns on embodiment of this invention does not contain a lipid, or contains a lipid in less than 1 mass%.
  • the mass per unit package of the composition for improving intellectual work ability is not particularly limited, 100 g is obtained from the viewpoint that the effect can be sufficiently obtained and it can be easily consumed at one time. It is preferably in the range of 1,000 g or less, more preferably in the range of 100 g or more and 800 g or less, further preferably in the range of 100 g or more and 600 g or less, and in the range of 100 g or more and 500 g or less. Most preferably it is. In addition, this content presupposes that protein is contained 2.0 mass% or more in the composition for intellectual work ability improvement.
  • unit packaging is not limited to unit packaging per bag, box, and container, but may be unit packaging per one time included therein or unit packaging per day. It should be noted that a plurality of days, for example, a quantity suitable for intake for one week may be packaged together, or may include a plurality of individual packages.
  • the amount of heat of the composition for improving intellectual work ability according to the embodiment of the present invention is not particularly limited, but is 0.2 kcal / mL or more from the viewpoint that a sufficient effect can be obtained and it is easy to ingest at one time. It is preferably within the range of 2 kcal / mL or less.
  • the composition for improving intellectual work ability has an effect quickly by single intake, but may be taken continuously. In this case, it is desirable to continuously ingest for 1 week or more, preferably 2 weeks or more, more preferably 4 weeks or more as an ingestion period.
  • the ingestion period is not particularly limited and can be continued permanently, for example, within one year.
  • this composition for intellectual work ability improvement may be continuously ingested only in a part of period, and may be ingested intermittently in arbitrary periods.
  • the composition for improving intellectual work ability according to the embodiment of the present invention can be used as a medicine or a food or drink.
  • the medicinal product or food or drink is useful in that it has an effect of improving intellectual work ability.
  • a single protein may be used, or two or more kinds of proteins may be used in combination. Also good.
  • the state of the composition for improving intellectual work ability is not limited, and it is a paste, a spray-dried product, and a freeze-dried product.
  • the product can be used in the form of a product, a vacuum dried product, a drum dried product, a liquid product dispersed in a medium, a diluted product diluted with a diluent, a crushed product obtained by crushing a dried product with a mill or the like.
  • the composition for improving intellectual work ability according to the embodiment of the present invention can be a health functional food (dementia prevention food, etc.) or a sick food (dementia progression suppression food, etc.).
  • the functional health food system is intended for not only regular foods but also foods in the form of tablets, capsules, etc., taking into account trends in Japan and overseas and the consistency with conventional food systems for specified health use. .
  • two types of foods for specific health use (individual permission type) and functional foods (standard specification type) are defined.
  • dementia can be prevented by administering the composition for improving intellectual work ability according to the embodiment of the present invention to a human as a special-purpose food such as a food for specified health use or a nutritional functional food.
  • the “labeling” here should be a label suitable for each of pharmaceuticals, quasi drugs, health functional foods, foods for specified health use, general foods, health supplements, health foods and supplements.
  • the “display” here includes all displays for informing the consumer of the above description. This display only needs to be a display that allows the above-described display contents to be recalled / analogized, and may include any display regardless of the purpose of display, the display contents, the object / medium to be displayed, and the like.
  • the product formed by packaging the composition for improving the intellectual work ability is, for example, a food or drink
  • the food or drink has, for example, an indication of “for improving the intellectual work ability” or It is preferable that the indication “improves the ability of intellectual work”, the indication “for enhancing cognitive ability”, the indication “for enhancement of parasympathetic nerve activity”, etc. .
  • wording used for the display as described above is not limited to the above-described example, and may be a word having the same meaning as that.
  • various words such as “improves intelligent work efficiency” or “helps improve learning ability” may be allowed for the consumer.
  • the type of the food or drink is not particularly limited.
  • Foods and beverages include, for example, milk, processed milk, soft drinks, fermented milk, yogurt, cheese, other dairy products, bread, biscuits, crackers, pizza crusts, prepared powdered milk, liquid food, food for the sick, infant milk powder, etc. It may be food, food such as powdered milk for pregnant women and lactating women, and nutritional food.
  • the protein that is the active ingredient of the composition for improving intellectual work ability according to the embodiment of the present invention is used as it is, or it is mixed with other foods and drinks and food ingredients.
  • the manufacturing method in a normal food composition can be used.
  • the shape of food / beverage products used normally may be sufficient.
  • any shape such as solid (including powder and granule), paste, liquid, and suspension may be used, but not limited thereto.
  • milk drink, fermented milk, soft drink, jelly drink, tablet, and powdered food are more preferable, milk drink is more preferable, and container-packed drink is further preferable.
  • capacitance may be in the range of 100 mL or more and 1,000 mL or less, or in the range of 100 g or more and 1,000 g or less, for example.
  • Proteins that are active ingredients of the composition for improving intellectual work ability include water, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors, and functionality. Any component contained in normal foods such as ingredients and food additives can be added without problems.
  • protein or protein-containing raw materials commonly used in food production such as protein, soy protein, chicken egg protein, meat protein and other animal and vegetable proteins, and hydrolysates thereof are used as the protein source. can do.
  • sugar sources include processed starch (in addition to text phosphorus, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
  • Examples of the lipid source include animal oils such as lard and fish oil, fractionated oils thereof, hydrogenated oil and transesterified oil; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, and fractionated oils thereof. And vegetable oils such as hydrogenated oil and transesterified oil.
  • vitamins include vitamin A, carotenes, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline.
  • Examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
  • Examples of the organic acid include malic acid, citric acid, lactic acid, and tartaric acid.
  • Examples of the functional component include oligosaccharide, glucosamine, collagen, ceramide, royal jelly, polyphenol and the like.
  • Examples of food additives include emulsifiers, stabilizers, thickeners, gelling agents, sweeteners, sour agents, preservatives, antioxidants, pH adjusters, colorants, and fragrances.
  • Various milk-derived components such as butter, dairy minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, and lactose can be suitably used for the production of the food and drink according to the embodiment of the present invention. It is an example.
  • composition for improving intellectual work ability includes any component having an effect of improving brain function, such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), phosphatidylserine (PS). ), Arachidonic acid, astaxanthin, theanine, lecithin, or ⁇ -aminobutyric acid (GABA) may be added.
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • PS phosphatidylserine
  • GABA ⁇ -aminobutyric acid
  • the raw material may be any of natural products, processed natural products, synthetic products and / or foods containing a large amount thereof.
  • the composition for improving intellectual work ability significantly increases the parasympathetic nerve activity index (RMSSD and HF HRV).
  • the composition for improving intellectual work ability according to the embodiment of the present invention is a composition for enhancing parasympathetic nerve activity.
  • the increase of parasympathetic nerve activity index (RMSSD and HF HRV) is related to the improvement of cognitive ability and cognitive speed. Therefore, the composition for improving intellectual work ability according to the embodiment of the present invention can also be called a composition for improving cognitive ability and a composition for improving cognitive speed, and can also be called a composition for preventing dementia. .
  • the “cognitive speed” indicates a cognitive ability such as a memory ability, a computational ability, a language ability, a judgment ability, an execution ability, that is, a cognitive function processing speed.
  • the Uchida-Kraepelin test which will be described later, is known to be particularly excellent for evaluating the recognition speed and work speed (efficiency).
  • the protein which is an active ingredient of the composition for improving intellectual work ability according to the embodiment of the present invention can be used as a pharmaceutical for preventing dementia.
  • the protein can be used as a crushed or unground product.
  • the protein to be used may be used independently and may be utilized with multiple types.
  • the protein content in the above pharmaceuticals can be arbitrarily determined according to the purpose and application (preventive agent).
  • An example of the content is 2.0 to 100% by mass with respect to the total amount, but the present invention is not limited to this.
  • the dosage of a pharmaceutical comprising the above-mentioned protein as an active ingredient can be appropriately set in consideration of various factors such as the administration route, the age, weight, and symptoms of animals to be administered including humans.
  • a suitable dose 0.1 g to 1,000 g / kg / day can be mentioned as an active ingredient, but the present invention is not limited to this.
  • the amount when ingested for preventive purposes over a long period, the amount may be smaller than the above range.
  • there is no safety problem with this active ingredient it can be used in a larger amount than the above range.
  • the above-mentioned pharmaceutical dosage form is preferably a dosage form capable of oral administration in order to allow the protein to reach the intestine.
  • preferable dosage forms of the pharmaceutical product according to the present invention include tablets, pills, coated tablets, capsules, granules, powders, solutions, suspensions, emulsions, syrups, lozenges and the like.
  • These various preparations are prepared by adding protein, excipient, disintegrant, lubricant, stabilizer, colorant, flavoring agent, solubilizing agent, suspending agent, surfactant to the main protein in accordance with conventional methods. It can be formulated by mixing adjuvants that can be usually used in the pharmaceutical preparation technical field, such as coating agents.
  • the protein when used as a pharmaceutical product, for example, in the case of oral administration, the protein can be ingested as it is.
  • the protein for example, according to the general production method of pharmaceutical products, tablets, granules, powders, capsules, powders It can be.
  • the protein content in the above pharmaceuticals can be appropriately set according to the dosage form, usage, patient age, sex, degree of brain function, and other conditions.
  • the content is, for example, preferably in the range of 15 g / 100 g or more and 50 g / 100 g or less, and more preferably in the range of 20 g / 100 g or more and 40 g / 100 g or less.
  • the above medicine is preferably administered orally. By administering this medicine, the intellectual work efficiency is improved. Therefore, this pharmaceutical agent is useful for improving or preventing various symptoms caused by a decrease in brain function. Moreover, as long as the intellectual work ability improvement effect of this invention is not impaired, you may use together this pharmaceutical which uses a protein as an active ingredient, and another pharmaceutical, for example, another intellectual work ability improvement agent etc.
  • placebo beverages Emulsifying flavor, raw water, crystalline glucose, sodium citrate, stabilizer (thickening polysaccharide (including soy)), trehalose, flavor, vitamin B6 and acidulant 0.5: 89.0: 8 0.5, 0.27: 0.45: 1.0: 0.052: 0.00019: 0.24 and mixed at a blending ratio (mass ratio) to prepare a placebo beverage (corresponding to a comparative example) ( See Table 2 below).
  • the nutrition component display of the said protein containing drink and a placebo drink was as follows.
  • the single intake of the protein-containing beverage and the placebo beverage was 430 mL.
  • the calories of both the 430 mL protein-containing beverage and the placebo beverage were 176 kcal, whereas the protein and carbohydrate content was 16 g (protein) and 28 g (carbohydrate) for the protein-containing beverage, compared to 0 g ( Protein) and 42 g (carbohydrate).
  • the details of the Uchida-Kraepelin test are as follows.
  • the Uchida-Kraepelin inspection paper manufactured by Japan Mental Technology Laboratory Co., Ltd. was used as the inspection paper.
  • 2 sets of mental arithmetic were imposed on the subjects 30 minutes before the scheduled intake time of the test beverage, and 8 sets of mental arithmetic were imposed on the subjects at 15 minute intervals after 15 minutes from the time of intake of the test beverage.
  • the subjects before the start of mental calculation of the first set before ingesting the test beverage, the subjects repeated mental calculation for 20 seconds 5 times at 20-second intervals to practice the Uchida-Kraepelin test.
  • the score of the second set before the test drink intake was determined before the test drink intake. The standard score was.
  • the heart rate variability of subjects was measured using ActiHR4 manufactured by CamHtech. Specifically, ECHR electrodes were attached to two places of the subjects' breasts to connect ActiHR4, and heart rate variability was continuously measured and recorded from the start of the test to the end of the test.
  • the Uchida-Kraepelin test score and heart rate variability were statistically processed in consideration of the order effect and the timing effect. Of the 33 subjects, 2 dropped out for personal reasons and the other 2 violated the restrictions, so 29 subjects excluding these 4 subjects were subject to analysis.
  • the analysis target of Uchida-Kraepelin test score was the data for all 29 people, but the analysis target of heart rate variability remains because the data of 10 subjects who had measurement problems such as signal failure should have been excluded. The data for 19 people.
  • the Uchida-Kraepelin test score after ingesting the test beverage and the amount of change in the heart rate variability were determined for each subject.
  • the AUC value (Area Under the Curve: area value under the curve) was determined.
  • the AUC value was obtained by subtracting the second value from the first value for each subject, and the comparison between the groups was performed by Mann-Whitney U test.
  • protein-containing drinks not only have the effect of significantly increasing the intellectual work ability of subjects compared to placebo drinks (see FIGS. 1 and 2), but also parasympathetic nerve activity indices (RMSSD and HF HRV) ) Has also been found to have a significant effect (see FIGS. 3 to 6). From this result, protein-containing beverages are expected to contribute to the improvement of human cognitive abilities and to the prevention of dementia compared to placebo beverages.
  • composition for improving intellectual work ability supplies protein to humans by oral ingestion, humans can efficiently efficiently consume a large amount of energy in any space.
  • the active ingredient can be supplied.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention aborde le problème de la fourniture d'une composition destinée à améliorer la capacité de travail intellectuel et pouvant fournir efficacement un principe actif à des êtres humains, en tout lieu, sans grande consommation d'énergie. Selon la présente invention, la composition destinée à améliorer la capacité de travail intellectuel et la composition destinée à améliorer la capacité cognitive comprennent chacune une protéine en tant que principe actif. Ces compositions comprennent de préférence 2 % en masse ou plus de la protéine. La composition destinée à améliorer la capacité de travail intellectuel est de préférence sous la forme d'un liquide, c'est-à-dire une boisson, de préférence encore une boisson conditionnée.
PCT/JP2018/016724 2017-04-26 2018-04-25 Composition destinée à améliorer la capacité de travail intellectuel et composition destinée à améliorer la capacité cognitive Ceased WO2018199130A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201880010949.6A CN110312516A (zh) 2017-04-26 2018-04-25 智力工作能力提高用组合物及认知能力提高用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017087066A JP2018184369A (ja) 2017-04-26 2017-04-26 知的作業能力向上用組成物および認知能力向上用組成物
JP2017-087066 2017-04-26

Publications (1)

Publication Number Publication Date
WO2018199130A1 true WO2018199130A1 (fr) 2018-11-01

Family

ID=63919145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/016724 Ceased WO2018199130A1 (fr) 2017-04-26 2018-04-25 Composition destinée à améliorer la capacité de travail intellectuel et composition destinée à améliorer la capacité cognitive

Country Status (3)

Country Link
JP (1) JP2018184369A (fr)
CN (1) CN110312516A (fr)
WO (1) WO2018199130A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7011984B2 (ja) * 2018-07-13 2022-01-27 キリンホールディングス株式会社 注意機能および判断機能向上用組成物
JP2021171059A (ja) * 2020-04-21 2021-11-01 サンスター株式会社 遂行機能改善用組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0923848A (ja) * 1995-07-14 1997-01-28 Calpis Food Ind Co Ltd:The 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品
JP2007091656A (ja) * 2005-09-29 2007-04-12 Kyoto Univ 新規なオピオイド活性ペプチド、新規な抗不安ペプチド
WO2010058517A1 (fr) * 2008-11-20 2010-05-27 明治乳業株式会社 STIMULATEUR DE CELLULES NERVEUSES COMPRENANT IgG ET/OU UN FRAGMENT Fc D’IgG
JP2013521779A (ja) * 2010-03-12 2013-06-13 ネステク ソシエテ アノニム 栄養素の風味をマスクするための組成物及び該組成物の調製方法
WO2015194564A1 (fr) * 2014-06-16 2015-12-23 キリン株式会社 Composition pour améliorer une fonction d'apprentissage par mémorisation et/ou une fonction cognitive
WO2016127097A1 (fr) * 2015-02-06 2016-08-11 The Regents Of The University Of California Procédés et compositions pour améliorer la fonction cognitive

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5941709B2 (ja) * 1981-07-29 1984-10-09 カルピス食品工業株式会社 タンパク質含有酸性飲料の製造法
US6686165B2 (en) * 1997-05-20 2004-02-03 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer
JP3756837B2 (ja) * 2002-04-08 2006-03-15 日本ミルクコミュニティ株式会社 弱酸性乳飲料及びその製造方法
US20040005368A1 (en) * 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
CN1706263A (zh) * 2004-06-04 2005-12-14 黑龙江省完达山乳业股份有限公司 一种具有增长智力作用的奶粉
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
CN100418428C (zh) * 2005-12-17 2008-09-17 内蒙古伊利实业集团股份有限公司 一种奶粉
JP2010137047A (ja) * 2008-12-12 2010-06-24 Samsung Electronics Co Ltd 頭脳活動向上機器及び皮膚老化防止機器
JP2012012358A (ja) * 2010-07-02 2012-01-19 Morinaga Milk Ind Co Ltd 脳機能改善剤及び脳機能改善用飲食品
CN104981172B (zh) * 2013-01-23 2017-09-05 En大冢制药株式会社 液状营养组合物
WO2015086789A1 (fr) * 2013-12-13 2015-06-18 Nestec S.A. Utilisation de lactosérum doux modifié et latosérum doux modifié contenant un lait artificiel destiné à favoriser le développement post-natal du système nerveux central du nourrisson et des fonctions cognitives y relatives
JP6494928B2 (ja) * 2014-06-06 2019-04-03 三栄源エフ・エフ・アイ株式会社 乳成分を含有する飲食品
WO2016013617A1 (fr) * 2014-07-23 2016-01-28 一般財団法人糧食研究会 Agent d'amélioration de fonction cérébrale, et agent prophylactique ou thérapeutique pour dysfonctionnement cognitif
CN104222286A (zh) * 2014-10-15 2014-12-24 张德信 改善智力的保健牛奶及其制备方法
JP6490944B2 (ja) * 2014-10-21 2019-03-27 株式会社Adeka 乳風味付与材
WO2016068251A1 (fr) * 2014-10-30 2016-05-06 株式会社明治 Boisson à base de lait acide et son procédé de production
CN105166629A (zh) * 2015-10-27 2015-12-23 江西美庐乳业集团有限公司 一种帮助改善学生记忆、提升注意力的营养包
CN108137650B (zh) * 2015-11-16 2022-04-08 麒麟控股株式会社 肽组合物及其制造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0923848A (ja) * 1995-07-14 1997-01-28 Calpis Food Ind Co Ltd:The 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品
JP2007091656A (ja) * 2005-09-29 2007-04-12 Kyoto Univ 新規なオピオイド活性ペプチド、新規な抗不安ペプチド
WO2010058517A1 (fr) * 2008-11-20 2010-05-27 明治乳業株式会社 STIMULATEUR DE CELLULES NERVEUSES COMPRENANT IgG ET/OU UN FRAGMENT Fc D’IgG
JP2013521779A (ja) * 2010-03-12 2013-06-13 ネステク ソシエテ アノニム 栄養素の風味をマスクするための組成物及び該組成物の調製方法
WO2015194564A1 (fr) * 2014-06-16 2015-12-23 キリン株式会社 Composition pour améliorer une fonction d'apprentissage par mémorisation et/ou une fonction cognitive
WO2016127097A1 (fr) * 2015-02-06 2016-08-11 The Regents Of The University Of California Procédés et compositions pour améliorer la fonction cognitive

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAKAMURA, H. ET AL.: "Influences of casein hydrolysate ingestion on cerebral activity, autonomic nerve activity, and anxiety", J PHYSIOL ANTHROPOL, vol. 29, no. 3, 2010, pages 103 - 108, XP055328588 *

Also Published As

Publication number Publication date
CN110312516A (zh) 2019-10-08
JP2018184369A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
ES2635764T3 (es) Método de producción de un producto alimenticio funcional basado en yema de huevo y productos obtenibles por el mismo
TWI722992B (zh) 腦功能改善劑、及認知功能障礙的預防或治療劑
ES2426481T3 (es) Polvos nutricionales que comprenden HMB secado por pulverización
CA3182755A1 (fr) Formule nutritionnelle
JP4687863B2 (ja) リン脂質含有の安定なマトリックスを含んでいる機能食品
WO2018199130A1 (fr) Composition destinée à améliorer la capacité de travail intellectuel et composition destinée à améliorer la capacité cognitive
JP6037595B2 (ja) 満腹感誘導組成物及びその製造方法
Falcão et al. Infant Formulas: a long story
JP7065589B2 (ja) ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳
JP5002442B2 (ja) 脂質吸収促進剤
JP2019081733A5 (fr)
JP7383874B2 (ja) エンドトキシンの血中移行阻害用組成物
US20150238447A1 (en) Beta-hydroxy-beta-methylbutryic acid-containing compositions and uses thereof
JP6752659B2 (ja) 更年期障害の改善剤
CN113840541A (zh) 膳食丁酸酯及其用途
JPWO2018123873A1 (ja) 発汗促進用組成物
US20220400704A1 (en) Composition for Enteral Intake
CN120225074A (zh) 肌肉肌醇和预防加速生长
CN117255621A (zh) 营养组合物及其相关方法
TW201233328A (en) Reduced buffering capacity of a low calorie infant formula
HK1230931A1 (en) Brain function improving agent, and prophylactic or therapeutic agent for cognitive dysfunction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18790121

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18790121

Country of ref document: EP

Kind code of ref document: A1